A new bioassay for measuring the strength of IL-6/STAT3 signal inhibition by tocilizumab in patients with rheumatoid arthritis

Interleukin-6 (IL-6) transduces signals via phosphorylation of STAT3 (pSTAT3). Tocilizumab (TCZ) is an IL-6 receptor blocker, which, when administered intravenously every 4 weeks, efficiently ameliorates rheum...

Source: Arthritis Research and Therapy - October 17, 2017 Category: Rheumatology Authors: Shuntaro Saito, Katsuya Suzuki, Keiko Yoshimoto, Yuko Kaneko, Yoshihiro Matsumoto, Kunihiro Yamaoka and Tsutomu Takeuchi Tags: Research article Source Type: research